3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasm Metastasis
9
Colorectal Neoplasms
7
Rectal Neoplasms
5
Colorectal Cancer Metastatic
5
Ovarian Neoplasms
4
Neoplasms
4
Lung Neoplasms
3
Colonic Neoplasms
3
Uveal Melanoma
2
Melanoma
2
Fallopian Tube Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma
2
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Stomach Neoplasms
1
Somatostatinoma
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Oligodendroglioma
1
Neurofibromatosis 2
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Multiple Endocrine Neoplasia Type 1
1
Macular Degeneration
1
Interventions
Gemcitabine
153
Fluorouracil
45
Capecitabine
45
130-nm albumin-bound paclitaxel
43
Oxaliplatin
42
Albumin-Bound Paclitaxel
39
Leucovorin
31
Erlotinib Hydrochloride
30
pembrolizumab
23
Radiotherapy
22
Irinotecan
22
Radiosurgery
20
Bevacizumab
19
Docetaxel
17
Cyclophosphamide
17
Taxes
13
Cisplatin
13
Cetuximab
13
folfirinox
12
Nivolumab
11
Surgical Procedures, Operative
7
Paclitaxel
7
Ipilimumab
7
dehydroftorafur
6
Standard of Care
6
Radiation
6
Magnetic Resonance Spectroscopy
6
spartalizumab
5
ruxolitinib
5
durvalumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Pancreatic Neoplasms
×
aflibercept
×
Clear all
NCT00574275
2016-06-07
VANILLA
Sanofi
Phase 3
Terminated
546 enrolled
14 charts